Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ravoet

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Blood|June 14, 2000
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)N Mounier, C Haioun, B F Cole, et al.
Acta Clinica Belgica|December 3, 2014
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing surveyY Beguin, D Selleslag, S Meers, et al.
Blood|August 10, 1999
Genes encoding tumor-specific antigens are expressed in human myeloma cellsN van Baren, F Brasseur, D Godelaine, et al.
Bone Marrow Transplantation|April 2, 2014
Impact of uncontrolled freezing and long-term storage of peripheral blood stem cells at - 80 °C on haematopoietic recovery after autologous transplantation. Report from two centresG Detry, L Calvet, N Straetmans, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Blood|June 14, 2000
Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA)N Mounier, C Haioun, B F Cole, et al.
Acta Clinica Belgica|December 3, 2014
Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing surveyY Beguin, D Selleslag, S Meers, et al.
Blood|August 10, 1999
Genes encoding tumor-specific antigens are expressed in human myeloma cellsN van Baren, F Brasseur, D Godelaine, et al.
Bone Marrow Transplantation|April 2, 2014
Impact of uncontrolled freezing and long-term storage of peripheral blood stem cells at - 80 °C on haematopoietic recovery after autologous transplantation. Report from two centresG Detry, L Calvet, N Straetmans, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Leukemia|February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agentsC Kelaidi, S Park, R Sapena, et al.
Pageof 3